Abstract
The in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml).
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Azithromycin / pharmacology
-
Barbiturates / pharmacology*
-
Chlamydia trachomatis / drug effects*
-
Chlamydia trachomatis / enzymology
-
Chlamydia trachomatis / growth & development
-
Chlamydophila pneumoniae / drug effects*
-
Chlamydophila pneumoniae / enzymology
-
Chlamydophila pneumoniae / growth & development
-
DNA Gyrase / metabolism*
-
Doxycycline / pharmacology
-
Isoxazoles
-
Levofloxacin / pharmacology
-
Microbial Sensitivity Tests
-
Morpholines
-
Oxazolidinones
-
Spiro Compounds / pharmacology*
-
Topoisomerase II Inhibitors / pharmacology*
Substances
-
Anti-Bacterial Agents
-
Barbiturates
-
Isoxazoles
-
Morpholines
-
Oxazolidinones
-
Spiro Compounds
-
Topoisomerase II Inhibitors
-
Levofloxacin
-
Azithromycin
-
DNA Gyrase
-
zoliflodacin
-
Doxycycline